AbbVie Inc

ABBV remains in Stage 2 advancing corrective reset within a longer-term uptrend, driven by an active Parabola pattern signaling steep acceleration but heightened reversal risk. Price is extended above rising EMAs and tagged overbought, suggesting caution. The medium-term bias stays bullish on intact HH/HL structure and EMA support. Short-term timing is neutral; we will stalk for a shallow pullback into the 9/21 EMA cluster before engaging under the Growth at Reasonable Price framework.

• ↑Q1 adjusted EPS of $2.65 beat guidance by $0.07 on 12.4% YoY revenue growth to $15 billion.
• ↑Skyrizzy commands over 45% psoriasis market share, boosting immunology revenues.
• ↓Humira revenues plunged 40.3% YoY after biosimilar launches, eroding cash flow.